Six oral SGLT2 inhibitors are currently approved for the treatment of type 2 diabetes mellitus (T2DM) by the US Food and Drug Administration (FDA) together with the European Medicines Agency (EMA): canagliflozin (CANA), empagliflozin (EMPA), dapagliflozin (DAPA), ertugliflozin (ERTU), bexagliflozin, and sotagliflozin. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.